230 related articles for article (PubMed ID: 32245893)
21. Changes in utilization and costs for patients with rheumatoid arthritis, 1997 to 2006.
Birnbaum HG; Pike C; Banerjee R; Waldman T; Cifaldi M
Pharmacoeconomics; 2012 Apr; 30(4):323-36. PubMed ID: 22379953
[TBL] [Abstract][Full Text] [Related]
22. Costs of rheumatoid arthritis during the period 1990-2010: a register-based cost-of-illness study in Sweden.
Kalkan A; Hallert E; Bernfort L; Husberg M; Carlsson P
Rheumatology (Oxford); 2014 Jan; 53(1):153-60. PubMed ID: 24136064
[TBL] [Abstract][Full Text] [Related]
23. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis.
Furneri G; Mantovani LG; Belisari A; Mosca M; Cristiani M; Bellelli S; Cortesi PA; Turchetti G
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S72-84. PubMed ID: 23072761
[TBL] [Abstract][Full Text] [Related]
24. Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico.
Tundia N; Kotze PG; Rojas Serrano J; Mendes de Abreu M; Skup M; Macaulay D; Signorovitch J; Chaves L; Chao J; Bao Y
J Med Econ; 2016 Dec; 19(12):1187-1199. PubMed ID: 27376404
[TBL] [Abstract][Full Text] [Related]
25. Rheumatoid arthritis and work: The impact of rheumatoid arthritis on absenteeism and presenteeism.
Verstappen SM
Best Pract Res Clin Rheumatol; 2015 Jun; 29(3):495-511. PubMed ID: 26612244
[TBL] [Abstract][Full Text] [Related]
26. The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey.
Malhan S; Pay S; Ataman S; Dalkilic E; Dinc A; Erken E; Ertenli I; Ertugrul E; Gogus F; Hamuryudan V; Inanc M; Karaarslan Y; Karadag O; Karakoc Y; Keskin G; Kisacik B; Kiraz S; Oksel F; Oksuz E; Pirildar T; Sari I; Soy M; Senturk T; Taylan A
Clin Exp Rheumatol; 2012; 30(2):202-7. PubMed ID: 22546069
[TBL] [Abstract][Full Text] [Related]
27. Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada.
Foo J; Morel C; Bergman M; Baerwald C; Rodriguez-Heredia JM; Marshall A; Polanco-Sánchez C; Postema R
Rheumatol Int; 2019 Sep; 39(9):1621-1630. PubMed ID: 31240388
[TBL] [Abstract][Full Text] [Related]
28. The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis.
Silverman S; Dukes EM; Johnston SS; Brandenburg NA; Sadosky A; Huse DM
Curr Med Res Opin; 2009 Apr; 25(4):829-40. PubMed ID: 19220165
[TBL] [Abstract][Full Text] [Related]
29. Economic benefits of optimizing anchor therapy for rheumatoid arthritis.
Fautrel B
Rheumatology (Oxford); 2012 Jun; 51 Suppl 4():iv21-6. PubMed ID: 22685272
[TBL] [Abstract][Full Text] [Related]
30. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
[TBL] [Abstract][Full Text] [Related]
31. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.
Michaud K; Messer J; Choi HK; Wolfe F
Arthritis Rheum; 2003 Oct; 48(10):2750-62. PubMed ID: 14558079
[TBL] [Abstract][Full Text] [Related]
32. Disease-modifying antirheumatic drug initiation among patients newly diagnosed with rheumatoid arthritis.
Bonafede M; Johnson BH; Shah N; Harrison DJ; Tang D; Stolshek BS
Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP279-SP285. PubMed ID: 30020740
[TBL] [Abstract][Full Text] [Related]
33. Societal costs of rheumatoid arthritis in China: a hospital-based cross-sectional study.
Xu C; Wang X; Mu R; Yang L; Zhang Y; Han S; Li X; Wang Y; Wang G; Zhu P; Jin H; Sun L; Chen H; Cui L; Zhang Z; Li Z; Li J; Zhang F; Lin J; Liu X; Hu S; Yang X; Lai B; Li X; Wang X; Su Y; Li Z
Arthritis Care Res (Hoboken); 2014 Apr; 66(4):523-31. PubMed ID: 24023001
[TBL] [Abstract][Full Text] [Related]
34. Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis.
Popp RA; Rascati K; Davis M; Patel U
Pharmacotherapy; 2018 Feb; 38(2):172-180. PubMed ID: 29197108
[TBL] [Abstract][Full Text] [Related]
35. Medical Care Costs Associated With Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta-Analysis.
Hresko A; Lin TC; Solomon DH
Arthritis Care Res (Hoboken); 2018 Oct; 70(10):1431-1438. PubMed ID: 29316377
[TBL] [Abstract][Full Text] [Related]
36. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
Clark W; Jobanputra P; Barton P; Burls A
Health Technol Assess; 2004 May; 8(18):iii-iv, ix-x, 1-105. PubMed ID: 15130461
[TBL] [Abstract][Full Text] [Related]
37. Societal costs of rheumatoid arthritis in Hong Kong: a prevalence-based cost-of-illness study.
Zhu TY; Tam LS; Li EK
Rheumatology (Oxford); 2011 Jul; 50(7):1293-301. PubMed ID: 21330341
[TBL] [Abstract][Full Text] [Related]
38. The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis.
Boonen A; Mau W
Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S112-7. PubMed ID: 19822056
[TBL] [Abstract][Full Text] [Related]
39. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.
Ollendorf DA; Peterson AN; Doyle J; Huse DM
Am J Manag Care; 2002 May; 8(7 Suppl):S203-13. PubMed ID: 12022236
[TBL] [Abstract][Full Text] [Related]
40. Early rheumatoid arthritis 6 years after diagnosis is still associated with high direct costs and increasing loss of productivity: the Swedish TIRA project.
Hallert E; Husberg M; Kalkan A; Skogh T; Bernfort L
Scand J Rheumatol; 2014; 43(3):177-83. PubMed ID: 24354438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
